Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine
Abstract : To determine predictors of substantial weight gain ( SWG ) during treatment of bipolar disorder with olanzapine , data were pooled from 4 long-term r and omized , multicenter studies in patients with bipolar mania or mixed mania ( N = 948 at initiation of olanzapine ) .  SWG was defined as gaining 5 kg or 7 % of initial weight in 30 ± 2 weeks . Logistic regression estimated odds ratios associated with early weight gain and baseline risk factors for predicting SWG . A classification system to identify patients at risk for  SWG was constructed by recursive data partitioning . Baseline characteristics significantly associated with SWG included younger age , nonwhite ethnicity , lower body mass index ( BMI ) , nonrapid cycling , and psychotic features . Weight gain of 2 or more kg in the first 3 weeks of therapy predicted SWG by 30 weeks ( sensitivity = 57 % ; specificity = 71 % ) . A classification system with thresholds for early weight gain , baseline BMI , and ethnicity further improved SWG predictability ( sensitivity = 79 % ; specificity = 70 % ) . In conclusion , patients with bipolar disorder who gained 2 to 3 kg during the first 3 weeks of treatment with olanzapine  , SWG was predicted after 30 weeks of treatment . Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI ( ≤27 kg/m2 ) at treatment initiation
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .